KYNTRA BIO, INC. Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment
KYNTRA BIO, INC. (KYNB) reported Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-06.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment · last filed 2024-05-06
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2024-03-31 was $0.00.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2023-12-31 was $0.00.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2023-09-30 was $0.00.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2023-06-30 was $0.00.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for fiscal 2023 was -$271.00K.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for fiscal 2022 was -$5.00K.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for fiscal 2021 was $0.00.
- KYNTRA BIO, INC. debt securities, available-for-sale, realized gain (loss), excluding other-than-temporary impairment for fiscal 2020 was -$258.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-06 | $0.00 derived: sum of 2 quarters · filed 2024-05-06 | $0.00 derived: sum of 3 quarters · filed 2024-05-06 | $0.00 derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $0.00 derived: sum of 3 quarters · filed 2024-02-26 | -$271.00K 10-K · filed 2024-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | -$271.00K 10-Q · filed 2023-11-06 | -$271.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$271.00K 10-Q · filed 2023-08-07 | -$271.00K derived: sum of 3 quarters · filed 2024-05-06 | -$271.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-03-31 | -$271.00K 10-Q · filed 2024-05-06 | -$271.00K derived: sum of 2 quarters · filed 2024-05-06 | -$271.00K derived: sum of 3 quarters · filed 2024-05-06 | -$271.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $0.00 derived: sum of 3 quarters · filed 2024-02-26 | -$5.00K 10-K · filed 2024-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | -$5.00K 10-Q · filed 2023-11-06 | $3.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$5.00K 10-Q · filed 2023-08-07 | $3.00K derived: sum of 3 quarters · filed 2024-02-26 | $3.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$5.00K 10-Q · filed 2023-05-08 | $3.00K derived: sum of 2 quarters · filed 2024-02-26 | $3.00K derived: sum of 3 quarters · filed 2024-02-26 | -$5.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $8.00K derived: sum of 2 quarters · filed 2024-02-26 | $0.00 derived: sum of 3 quarters · filed 2024-02-26 | $0.00 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$8.00K derived: sum of 2 quarters · filed 2022-11-07 | -$8.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$8.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$258.00K 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $0.00 10-K/A · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |